Addressing Unmet Needs for Patients with CLL on Zanubrutinib
Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib.
Zanubrutinib/Venetoclax Shows Efficacy in High-Risk CLL Subgroup
Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Unmet Needs in Frontline Treatment of CLL
The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.
Advice for Ibrutinib-Intolerant Patients
Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.
Tolerability of Ibrutinib, Zanubrutinib, and Acalabrutinib
Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.
Approved BTKi Frontline Treatments for CLL
Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).
Examining the Role of Frontline BTKi Monotherapy in CLL
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
Pooled Analysis Supports Use of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.
Dr. Brown Discusses New Drugs on the Horizon in CLL
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, discusses new drugs on the horizon for the treatment of patients with chronic lymphocytic leukemia (CLL).
2 Clarke Drive Cranbury, NJ 08512